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Introduction
Janus Kinase 2 (JAK2) is a non-receptor tyrosine kinase that transduces the signal from 
several cytokine receptors including the erythropoietin (Epo), G-CSF, and thrombopoietin 
(Tpo) receptors. Depending on the receptor to which it is bound, JAK2 can activate multiple 
signal transduction pathways, including activation of several STAT proteins as well as the 
PI-3′kinase/Akt, Ras/MAPK, and other signaling pathways essential for cytokine-mediated 
cell survival, proliferation, and differentiation (1). The N-terminal JAK2 FERM domain is 
critical for binding of JAK2 to receptors, followed by an SH2 domain that may play a role in 
JAK2 activation (2). The pseudokinase domain normally inhibits the C- terminal kinase 
domain (3).
Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis 
(PMF) are myeloproliferative neoplasms (MPN) caused by the abnormal clonal expansion of 
hematopoietic precursors and/or panhyperplasia of myeloid cells. Progression leads to bone 
marrow fibrosis and extramedullary hematopoiesis (4). A somatic mutation in JAK2, V617F, 
is found in more than 90% of patients with PV and half of those with ET or PMF (5–8). The 
pathogenicity of JAK2 V617F was further confirmed by JAK2 V617F knock-in mouse 
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models that developed MPN-like symptoms (9–12). The pathogenic V617F mutation is 
located in the pseudokinase domain, disrupting kinase inhibition by the pseudokinase 
domain; this triggers constitutive activation of JAK2 but only in cells co-expressing a 
dimeric cytokine receptor such as the EpoR, TpoR, or G-CSFR(13–15). In particular, JAK2 
V617F binds to the EpoR and triggers hyper-activation of downstream signaling pathways 
such as STAT5, ERK, and AKT both in the absence and presence of low Epo levels (9,12).
The effects of JAK2 V617F on early hematopoietic development are many. Hasan et al. 
found that JAK2 V617F promotes amplification of early hematopoietic cells in a mouse 
knock-in model (16), while Kent et al. found that JAK2 V617F reduces self-renewal of 
single hematopoietic stem cells (HSCs) (17). However, Mullally et al. suggested that HSCs 
expressing JAK2 V617F does not have a significant competitive advantage over wild-type 
HSCs (12,18).
JAK2 V617F does simulate some abnormal signaling pathways in early hematopoietic 
development. JAK2 V617F binds to PRMT5, a type II arginine methyltransferase, more 
tightly than JAK2, and activates PRMT5 by phosphorylation. Activated PRMT5 alters 
chromatin modifications and impairs hematopoietic differentiation, resulting in an elevated 
number of BFU-Es (19). JAK2 V617F also increases expression of CDC25A, a key 
regulator of the cell cycle, and NF-E2, an erythroid important transcription factor. 
Overexpression of these genes causes abnormal expansion of myeloid and erythroid 
progenitors (18–21). In addition, JAK2 V617F hyper-activates Stat3 and Stat5 in bone 
marrow cells and CD34+ cells from patients, and activates Stat1, which is normally inactive, 
in mature erythroblasts derived from erythroid progenitors from ET patients (22–24). 
However, there has been no systematic study of signal transduction pathways or gene 
expression in cells expressing JAK2 V617F during Epo-dependent terminal erythroid 
differentiation.
While knock-in mouse models that express JAK2 V617F have been developed and develop 
MPN-like symptoms(9–12), purification of Epo- dependent erythroid progenitors at the 
same developmental stage from normal and JAK2 V617F knock-in mice has not been 
accomplished. Thus for our studies we used lineage negative (Lin−) fetal liver cells from 
E14.5 C57BL/6J mice that are enriched for Epo- dependent erythroid progenitors, mainly 
Colony- Forming Units Erythroid (CFU-Es). When normal Lin- murine fetal liver 
progenitors are placed in culture containing only Epo, they undergo a stereotypic 
differentiation process involving 4–5 cell divisions over 2–3 days, induction of globins, 
heme synthesizing enzymes, and ~400 other essential erythroid genes, chromatin 
condensation, and enucleation in a manner similar to differentiation of erythroblasts in vivo 
(25).
Here we show that Lin- fetal liver progenitors ectopically expressing JAK2 V617F produce 
many more RBCs than normal. Expression of JAK2 V617F does not affect the initial rate of 
cell division but the cells continue to undergo ~6 rather than ~4 cell divisions. After 48 hours 
in culture, all control cells or cells ectopically expressing wild-type JAK2 have exited the 
cell cycle, are fully hemoglobinized, and most have enucleated. In contrast, at 48 hours cells 
expressing JAK2 V617F are larger and less hemoglobinized than normal and express higher 
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levels of Myb and other transcription factors characteristic of early erythroid progenitors. 
These cells express many genes not normally activated in terminally differentiating erythroid 
cells and that are characteristic of other hematopoietic lineages. Over the next two days 
these cells divide ~2 additional times and eventually accumulate normal amounts of 
hemoglobin, condense their nuclei, and enucleate. Thus expression of JAK2 V617F in Epo- 
dependent progenitors delays but does not prevent terminal differentiation.
Strikingly, global gene expression profiling and western blotting of JAK2 V617F expressing 
cells indicate that in addition to signaling pathways normally activated by EpoR, several 
signal transduction proteins not normally activated during terminal erythroid proliferation 
and differentiation, including Stat1 and Stat3 are activated and Stat5 is hyperactivated. We 
also show that these fetal liver erythroid progenitors cells express many cytokine receptors 
additional to the EpoR. It is likely that binding of JAK2 V617F to some of these non-
erythroid receptors activates non-erythroid-signaling pathways that delays terminal erythroid 
differentiation and permits extended numbers of cell divisions. Inhibiting the activation of 
Stat1 by Fludarabine blocks erythroid hyper-proliferation in cells expressing JAK2 V617F. 
We hypothesize that these abnormal signaling pathways interfere with normal EpoR-JAK2 
signaling, delay cell cycle exit and terminal differentiation, and thus lead over time to more 
RBCs produced from each CFU-E progenitor.
Material and methods
Plasmids
The bicistronic MSCV vectors expressing JAK2 or JAK2 V617F and GFP were gifts from 
Prof. Wei Tong at the University of Philadelphia.
Antibodies
The antibody for Jak2 was from EMD Millipore (06-1310). The antibody for Gapdh was 
from Santa Cruz (FL-335). The antibodies for Stat1(14994), phospho-Stat1 (9167), 
Stat3(12640), phospho-Stat3 (9145), Stat5 (9363), phospho-Stat5 (4322), Stat6 (5397), 
CSF2RB (3432), GP130 (3732) and CXCR4 (97680) were from Cell Signaling. The 
antibodies for IFNGR1 (ab61179), phospho-IFNGR1 (ab61062) and phospho-CXCR4 
(ab74012) were from Abcam.
Murine fetal erythroid progenitor cell purification and differentiation
Enriched erythroid progenitors were purified from E14.5 C57BL/6J mouse embryos, and 
underwent in vitro differentiation following a protocol described previously in detail (26,27). 
Briefly, Day 14.5 pregnant C57BL/6J mice were euthanized by carbon dioxide. The 
embryos were isolated and the entire fetal livers were collected in Phosphate Buffered Saline 
(PBS) containing 2% Fetal Bovine Serum (FBS) and 100 μM EDTA. After repeated 
suspension through pipette tips and filtration through a 70 μm filter (BD), the fetal liver cells 
were incubated with an Ammonium Chloride Solution (Stemcell) for lysis of red blood cells. 
After 10 minutes the remaining fetal liver cells were centrifuged at 1500 RPM for 5 minutes 
and re-suspended in PBS. Following the manufacturer’s protocol, lineage negative cells were 
obtained after magnetic depletion of lineage positive cells using the BD Biotin Mouse 
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Lineage Panel (559971) and BD Streptavidin Particles Plus – DM (557812). These lineage 
negative fetal liver cells were enriched more than 90% for erythroid progenitors.
Retrovirus production and infection
MSCV-based retroviruses were produced and used to infect erythroid progenitors following 
a previously described protocol (27). Briefly, after isolation, lineage negative fetal liver cells 
were plated in 24-well plates with 100,000 cells per well, covered by 1 ml virus containing 
supernatant, and centrifuged at 2000 RPM for 90 min at 37°C. After spin-infection, the virus 
supernatant was replaced with erythroid maintenance medium (StemSpan-SFEM (StemCell 
Technologies) with added recombinant mouse stem cell factor (100 ng/ml SCF, R&D), 
recombinant mouse IGF-1 (40 ng/ml, R&D), dexamethasone (100 nM, Sigma), and 
erythropoietin (2 u/ml, Amgen)). The cells were cultured overnight for recovery and 
expression of transgenes. The next morning, the infected cells were pooled and sorted for 
green fluorescence by FACS sorting at a flow rate 2. Following our published protocol for 
culture and terminal erythroid differentiation (26, 27), the GFP+ cells were cultured in Epo-
only erythroid differentiation medium (Iscove modified Dulbecco’s medium (IMDM) 
containing 15% FBS (Stemcell), 1% detoxified bovine serum albumin (BSA) (Stemcell), 
500 μg/mL holo-transferrin (Sigma-Aldrich), 0.5 U/mL Epo (Amgen), 10 μg/mL 
recombinant human insulin (Sigma-Aldrich), 2 mM L-glutamine (Invitrogen) and 1× Pen 
Strep (Invitrogen)).
Number of cell divisions
Fetal liver lineage negative erythroid progenitors were labeled with PKH26 as described 
previously (28); we calculated the number of cell division based on the mean fluorescence 
intensity of PKH26 measured at different times of culture.
Microarray analysis
Agilent one-color arrays were quantile normalized. If a gene was represented by multiple 
probes in an array, its average probe expression value was used. Differential expression 
analysis was performed using a moderated t-test, as implemented in the limma package of 
Bioconductor, with P-value correction for false discovery rate. Log2 ratios of mean 
expression levels (treatment/control) and false discovery rate (FDR)-adjusted P-values were 
used for further analysis. Hierarchical clustering was obtained using hclust method with 
complete linkage and Euclidean distance in R. Analysis of gene expression across 30 tissues 
and cells followed the protocol used previously(29).
Inhibition of Stat1 and Stat3 activation by small molecule inhibitors
The Stat1 inhibitor Fludarabine (Santa Cruz Biotechnology, sc-204755) and the Stat3 
inhibitor Stattic (Santa Cruz Biotechnology, sc-202818) were dissolved in dimethyl 
sulfoxide (DMSO) at 200 mM and 50 mM, respectively, and added to the RBC 
differentiation medium at a final concentration of 1.5 μM.
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Cell apoptosis assay measured by Annexin V
Apoptosis of cell expressing Jak2 V617F after Stat1 or Stat3 inhibition was measured by the 
BD Pharmingen™ PE Annexin V Apoptosis Detection Kit following the manufacturer’s 
manual. Briefly, two million cells were collected and washed twice with cold phosphate 
buffered saline (PBS). After resuspended in 1* Binding Buffer at a concentration of 2 
million cells/ml, ten percent of the sample was incubated with 5 μl of PE Annexin V and 5 
μl 7-AAD for 15 mins at room temperature while covered by aluminum foil. The cells were 
then washed by PBS and analyzed by flow cytometry to detect Annexin V positive cells.
Colony forming assay
Cell concentration was determined using a hemocytometer (Hausser Scientific) after staining 
with Trypan Blue. Two hundred cells were mixed with 3 ml methylcellulose-based medium 
(Stemcell, MethoCult™ M3334), and plated in a 35 mm culture dish. Each experimental 
point contained two duplicate culture dishes plus one dish filled with water that were held in 
one 10 cm plate, and cultured at 37°C with 5% carbon dioxide for five days before 
examination under a microscope.
Standard techniques of hematology
Standard techniques used in hematology were performed following the protocols described 
before (25–27). These included flow cytometry (FACS) sorting and analysis, western 
blotting, colony forming assay, cell staining and microscopic analysis, hemoglobin 
measurement, RNA extraction and Quantitative RT–PCR analysis.
Results
Ectopic expression of JAK2 V617F promotes proliferation of Epo- dependent erythroid 
progenitors
We infected lineage negative fetal liver cells with bicistronic retroviral vectors expressing 
GFP and either JAK2 or JAK2 V617F (30). After an overnight culture (termed 0 hour) to 
allow expression of the transgenes, JAK2 and JAK2 V617F infected erythroid progenitors 
expressed a similar low level of GFP, suggesting a moderate expression level of JAK2 or 
JAK2 V617F. This was confirmed by Western blots, showing a 2 and 2.2-fold increased 
expression of JAK2 and JAK2 V617F, respectively, compared to endogenous JAK2 levels 
(Figure 1a). We then cultured these cells in medium containing only Epo for 96 hours. As 
normal terminal erythropoiesis is completed by 48 hours, we compared the expression levels 
of JAK2 and JAK2 V617F at 24 and 48 hours by Western Blots. Based on the ratio of JAK2 
expression to that of the internal control GAPDH, the expression level of ectopic JAK2 
remained similar at 24 hours, but decreased at 48 hours, likely because the protein 
expression machinery had switched to produce hemoglobin. In contrast, the expression level 
of JAK2 V617F decreased greatly at 24 and 48 hours, although ectopic expression of JAK2 
and JAK2 V617F were driven by the same promoter. The decrease in JAK2 V617F might be 
due to feedback of aberrant JAK2 V617F signaling pathways (Figure 1a).
During the first 48 hours of culture, all cells expanded 16-fold with a similar 11–12 hour 
doubling time. But after 72 hours the number of control and JAK2 expressing cells 
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decreased due to lysis of enucleated reticulocytes. In contrast, cells expressing JAK2 V617F 
continued proliferating and reached a peak at 96 hours, resulting in a four-fold increase in 
the number of cells produced from each progenitor (Figure 1b).
Moreover, we labeled control, JAK2 and JAK2 V617F expressing progenitors at 0 hour with 
PKH26, a red fluorescent cell membrane dye, and monitored by flow cytometry the 
fluorescent densities of these cells during differentiation (28). Since the amount of PKH26 
decreases by one half after each cell division, the decrease in PKH26 fluorescence 
corresponds to the number of cell division. Control and JAK2- expressing cells divided 4 
times in the first 48 hours and then stopped dividing, but cells expressing JAK2 V617F later 
underwent nearly two extra divisions (Figure 1 c and d).
Ectopic expression of JAK2 V617F delays cell cycle exit and increases the number of 
colony forming units – erythroid (CFU-Es)
Cell cycle exit is a hallmark of terminal erythropoiesis (31). As expected, cells expressing 
the control vector or JAK2 exited the cell cycle by 48 hours of culture, as the majority of 
cells were in the G0/G1 phase. In contrast, cells expressing JAK2 V617F were actively 
proliferating at 48 hours as judged by the high percentage in the S and G2/M phases; and did 
not exit the cell cycle until 96 hours (Figure 1 e, f and S2). Importantly, most of cells 
expressing JAK2 V617F, JAK2, and control vector were committed erythroid progenitors, as 
evidenced by cell surface expression of Ter-119 at as early as 24 hours of culture (Figure 
S1).
CFU-Es are defined as committed erythroid progenitors able to give rise to colonies 
containing 8–32 fully hemoglobinized cells after 2–3 days of in vitro culture in medium 
containing only Epo. CFU-Es quickly lose their colony forming potential during terminal 
erythroid development. Of 200 Lineage- negative fetal liver progenitors plated, as expected 
about 100 were functional CFU-Es. Also as expected, cultures of progenitors expressing 
either a control vector or JAK2 lost colony-forming potential after 24 hr. In contrast, cultures 
of CFU-Es expressing JAK2-V617F exhibited a four -fold increase in functional CFU-Es 
after 24 hours in culture with Epo. Since these cells divided twice during the first 24 hr of 
culture, most if not all of the cells produced at 24 hr were, like the parental cell, a CFU-E. 
The loss of functional CFU-Es during the subsequent 24 hr. culture period (Figure 1g) is 
consistent with terminal erythroid differentiation, as documented below. Representative 
erythroid colonies from cultures expressing control, JAK2, and JAK2-V617F vectors at 0 
hour, and cultures expressing JAK2-V617F at 24 hours of culture (Figure 1h) exhibit normal 
morphology.
Ectopic expression of JAK2 V617F delays terminal erythropoiesis
To determine whether JAK2 V617F expression delays terminal erythroid differentiation, we 
studied the morphology of cells expressing control, JAK2, and JAK2 V617F at 48 hours, and 
JAK2 V617F at 96 hours of culture with Epo. At 48 hours normal erythroid progenitors and 
cells expressing JAK2 have, as expected, decreased in cell size, accumulated ~31 pg/cell 
hemoglobin, and undergone enucleation (26). At 48 hours cells expressing JAK2 V617F 
were larger and paler in color than normal (Figures 2a and S3) and had reduced amounts of 
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hemoglobin (Figure 2d); none had undergone enucleation (Figure 2c) Moreover, cells 
expressing JAK2 V617F expressed much lower than normal levels of many erythroid-
important genes and retained higher than normal expression levels of Myb and other 
transcription factors characteristic of early erythroid progenitors (Figure 2b). Nevertheless, 
cells expressing JAK2 V617F cells eventually differentiated. At 96 hours they had 
undergone enucleation at a slightly lower- than normal frequency, and accumulated normal 
hemoglobin levels (31 pg/cell), forming reticulocytes that were indistinguishable in size 
from controls (Figure 2c–f).
Expression of the constitutively active mutant EpoR R129C does not affect terminal 
erythroid proliferation or differentiation
To determine whether JAK2 V617F mediated terminal erythroid hyper-proliferation is 
driven only by the same pathways as normally activated by Epo, we overexpressed the 
disulfide-linked homodimeric and constitutively active EpoR R129C mutant in erythroid 
progenitors, and cultured them in erythroid differentiation medium(32). When cultured in 
the presence of Epo, cells expressing EpoR R129C underwent normal proliferation and 
differentiation, and enucleation at 48 hours. The sizes of the reticulocytes formed were 
normal (Figure 3 a–c). Without Epo, expression of EpoR R129C supported normal 
proliferation and differentiation of erythroid progenitors whereas normal erythroid 
progenitors did not divide and underwent apoptosis (Figure 3 d and e). These results suggest 
that constitutive hyper-activation of the EpoR neither disrupts terminal erythropoiesis nor 
delays erythroid differentiation.
As revealed by microarray analysis JAK2 V617F activates non-erythroid signaling 
pathways in Epo-dependent differentiating erythroblasts
To understand the molecular mechanisms by which expression of JAK2 V617F affects 
terminal erythroid proliferation and differentiation, we collected RNA samples from 
erythroid progenitors expressing the control vector, JAK2, or JAK2 V617F at 0, 24, 48 hours 
of culture, and two additional samples from cells expressing JAK2 V617F at 72 and 96 
hours. Global gene expression profiling was analyzed using Agilent Mouse Gene Expression 
Microarrays (Figure S4). Hierarchical clustering revealed that these cell populations 
segregated into four transcriptionally distinct groups: (1) All progenitor cells at 0 hours of 
culture, that is after the overnight pre-incubation to allow expression of the transgenes; (2) 
Control and JAK2 expressing cells at 24 hours; (3) Control and JAK2 expressing cells at 48 
hours together with JAK2 V617F expressing cells at 72 hours and 96 hours. (4) JAK2 
V617F expressing cells at 24 hours and 48 hours (Figure 4a). Groups 1, 2, and 3 correspond 
to normal erythroid progenitors, differentiating nucleated erythroblasts, and terminal 
erythroblasts and reticulocytes, respectively.
To confirm that JAK2 V617F delays terminal erythropoiesis, we selected the top 600 genes 
upregulated in Ter119+ erythroblasts compared to CFU-Es as markers for erythroid 
maturation(27). Half of these genes were expressed specifically in the erythroid lineage 
(Figure S5). Expression of these marker genes increased dramatically at 48 hours in cells 
expressing JAK2, but not in those expressing JAK2 V617F until 72 and 96 hours (Figure 
4b). Interestingly, cells expressing control or JAK2 exhibit nearly identical patterns of gene 
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expression at all-time points; only 0, 2 and 25 genes were differentially expressed greater 
than 2 fold in JAK2 expressing cells relative to control cells at 0, 24 and 48 hours, 
respectively. This extends data in Figures 1 and 2 showing that the slight overexpression of 
wild- type JAK2 does not affect terminal erythroid proliferation or differentiation. 
Consistent with our finding that cells expressing JAK2 V617F eventually underwent normal 
hemoglobinization and enucleation at 96 hours, the expression profile of cells expressing 
JAK2 V617F at 72 and 96 hours was virtually indistinguishable from those of control or 
JAK2 expressing terminally differentiated cells at 48 hours; the R2 of linear regression for 
36,551 mRNA expression values in JAK2 V617F expressing cells at 96 hours plotted against 
JAK2 cells at 48 hours was 0.9482 (Figure 4d).
Importantly, the transcriptional profile of cells expressing JAK2 V617F at 24 and 48 hours 
was very different from that of any normal differentiating erythroid cell (Figure 4a). 
Specifically, 423, 875 and 3868 genes were differentially expressed greater than 2 fold in 
JAK2 V617F cells at 0, 24 and 48 hours, relative to JAK2 expressing or control cells, 
respectively. We then used Gene Set Enrichment Analysis (GSEA) to identify differentially 
expressed gene sets using JAK2 V617F and JAK2 expressing cells at 0, 24 and 48 hours. As 
expected, the “DNA replication” gene set was enriched in JAK2 V617F expressing cells at 
48 hours, consistent with the delay of cell cycle exit and the continued cycling of these cells 
compared to control cells (Figure 4c). At 0 hours there were 20 gene sets significantly 
enriched in JAK2 V617F expressing erythroid progenitors, including “cytokine & cytokine 
receptor interaction”, “JAK-STAT signaling,” and many other immunological and 
inflammatory pathways that are not normally activated during erythropoiesis (Table 1). 
Leading edge analysis of these signaling pathways revealed that signaling molecules 
including TNFα, interleukin, interferon, TGFβ, EGF, and their receptors and downstream 
signal transduction proteins were common molecules among these signaling pathways 
(Figure 4e and Table S1).
Consistent with this, the 423 genes unregulated in erythroid progenitors expressing JAK2 
V617F were predominantly expressed in other hematopoietic lineages, including T cells, B 
cells, macrophages and megakaryocytes (Figure S6). During differentiation of JAK2 V617F 
cells, the expression of most of these 423 genes decreased gradually. (Table S1); as a 
consequence, most of the non-erythroid signaling pathways (13/20) were no longer enriched 
in erythroblasts expressing JAK2 V617F at 48 hours of differentiation (Table 1). The drop in 
expression of these non-erythroid genes in JAK2 V617F expressing cells is consistent with 
the eventual normal terminal differentiation of these cells.
JAK2 V617F activates abnormal STAT signaling in erythroid differentiation
Interestingly, in purified murine fetal liver Epo- dependent erythroid progenitors, which are 
characterized by low Ter119 and high CD71 expression, many cytokine receptors additional 
to EpoR, JAKs additional to JAK2, as well as several STATs additional to Stat5, are also 
expressed (Figure 5a) (25). Western blotting shows that, after being placed in medium 
containing only Epo for 2.5 hours, cells expressing JAK2 V617F hyper-phosphorylated 
Stat5 compared to control cells, consistent with previous findings(9,14). Strikingly, 
overexpression and activation of Stat1 and Stat3 were found only in cells expressing JAK2 
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V617F, but not in controls. STAT6 was also found in all cells, though no phosphorylated 
Stat6 was detected (Figure 5b). STAT2 and STAT4 were not detectable by western blotting.
Indeed, Stat1 and Stat3 likely activate a number of genes normally expressed in other 
hematopoietic lineages. By overlapping the chip-seq data of Stat1 in T cells and Stat3 in 
macrophages with our microarray data (33–35) we identified 203 potential Stat1- activated 
genes and 171 potential Stat3-activted genes that were specifically upregulated at 0 hour in 
JAK2 V617F cells, compared to cells expressing JAK2 (Figure S7 a and b). Most of these 
Stat1 and Stat3 activated genes were abundantly expressed in other hematopoietic lineages, 
but not normally in erythroid cells (Figure S7 c and d). In contrast, only the JAK2-Stat5 
signaling pathway is activated during normal CFU-E terminal erythropoiesis and prevents 
progenitor apoptosis and is essential for terminal proliferation and differentiation(36). It is 
highly likely that the non-erythroid genes and pathways activated by Stat1 and Stat3 
interfered with normal JAK2-Stat5 signaling pathways and blocked erythroid differentiation. 
Normal maturation of erythroblasts expressing JAK2 V617F could only occur after 
expression of these Stat1 and Stat3 activated genes had decreased (Figure S7).
Unlike JAK2, JAK2 V617F can bind to and activate dimeric cytokine receptors in the 
absence of cytokine simulation, and activate downstream signaling pathways (14,15). 
Expression of four cytokine receptors – interferon gamma receptor 1 (IFNGR1), C-X-C 
chemokine receptor type 4 (CXCR4), Glycoprotein 130 (GP130), and cytokine receptor 
common beta-chain (CSF2RB) – were identified by western blotting as being expressed in 
erythroid progenitors after culture in Epo-only medium for 2.5 hours. More importantly, 
IFNGR1 and CXCR4 were phosphorylated only in cells expressing JAK2 V617F, but not in 
differentiating control cells in the presence of Epo (Figure 5b). These results suggest that 
JAK2 V617F associates with and activates several cytokine receptors in CFU-Es in the 
absence of the normal activating cytokine, and subsequently activates non-erythroid 
downstream signaling pathways.
JAK2 V617F mediated erythroid terminal differentiation is Epo dependent
To examine whether Epo is indeed essential for JAK2 V617F terminal erythropoiesis, we 
cultured JAK2 V617F expressing progenitors in medium with or without Epo. Without Epo, 
the proliferation rate of JAK2 V617F expressing cells was much lower than with Epo 
(Figure 6a); only half of the cells became committed Ter-119 positive erythroblasts and only 
a few underwent enucleation (Figure 6 b and c). These results suggest that some Epo is 
essential for terminal erythroid differentiation despite the expression of JAK2 V617F.
Inhibition of activated Stat1 disrupts JAK2 V617F mediated erythroid hyper-proliferation
To examine whether Stat1 or Stat3 was essential for erythroid hyper-proliferation, we treated 
cells expressing JAK2 V617F with Stattic, a chemical inhibitor of Stat3, and Fludorabine, an 
inhibitor of Stat1, respectively. JAK2 V617F – expressing cells treated with 1.5 μM 
Fludarabine exhibited a significant less proliferation (Figure 7a) with increased apoptosis 
measured by Annexin V staining (Figure 7b). Western blot confirmed the reduction of 
phosphorylated Stat1 in the presence of Fludorabine comparing to cells treated with DMSO 
(Figure 7c). However inhibiting Stat3 activity by Stattic only slightly affected cell 
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proliferation. Our data suggests JAK2 V617F medicated erythroid terminal hyper-
proliferation depends on Stat1 phosphorylation by the constitutively active JAK2 V617F 
kinase.
Discussion
Our principal result is that expression of JAK2 V617F in murine fetal liver erythroid 
progenitors and cultured in the presence of Epo does not affect the rate of cell doubling – 
about 12 hours – but JAK2 V617F- expressing cells divide ~6 rather than the normal ~4 
times. Whereas normal terminally differentiating erythroid cells exit the cell cycle after 3 – 4 
divisions and undergo nuclear condensation and enucleation, those expressing JAK2 V617F 
delay cell cycle exit for ~2 additional divisions. But JAK2 V617F expressing erythroid 
progenitors eventually differentiate into apparently normal reticulocytes.
Microarray analyses comparing JAK2 and JAK2 V617F – expressing erythroblasts indicate 
that JAK2 V617F not only activates EpoR-JAK2 signaling pathways, but also transiently 
induces non-erythroid- signaling molecules including TNFα, interleukin, interferon, TGFß, 
EGFR, receptors and downstream signal transduction proteins. We further show the 
overexpression and activation of Stat1 and Stat3 signaling pathways only in progenitors 
expressing JAK2 V617F, but not in normal progenitors or those expressing JAK2.
Our explanation for this relates to the fact that JAK2 is essential for signal transduction by a 
large number of cytokine receptors, including the Epo, Tpo, G-CSF, prolactin, IL-3, IL-5, 
GM-CSF, IL-6, IL-12, and interferon gamma receptors (1). Of these, we show that fetal 
erythroid progenitor cells normally express several cytokine receptors additional to the Epo 
receptor, JAK1 and JAK3 additional to JAK2, and other STATs additional to STAT5 (25). 
Specifically, we show the expression of IFNGR1, CXCR4, GP130, and CSF2RB in 
erythroid progenitors by Western blotting; it is surprising for us to see how many cytokine 
receptors, in addition to the EpoR, were expressed in our mouse fetal liver erythroid cells 
(25,27).
Importantly, IFNGR1 and CXCR4 are activated (phosphorylated) only in cells expressing 
JAK2 V617F, but not in control or JAK2- expressing differentiating cells. IFNGR1 forms 
heterodimers with IFNGR2 and is associated with both JAK1 and JAK2 (37). CXCR4, a G 
protein-coupled receptor, is expressed on the surface of many cell types. Upon binding to 
CXC chemokine stromal-derived factor 1 (SDF-1α), CXCR4 activates the downstream 
JAK2/STAT3 signaling pathway (38). Additionally, a low level of terminal erythropoiesis 
can be stimulated by Tpo (39) and it is likely that some or all erythroid progenitors express 
low and possibly variable numbers of some of these other receptors. JAK2 V617F is known 
to bind to and activate the Epo, Tpo, IGF, and prolactin receptors(40) and likely can bind to 
and activate other cytokine receptors in the absence of the cognate cytokine and activate 
signaling pathways characteristic of these receptors as discussed previously (41,42).
The exact signaling pathways activated in any particular cell by JAK2 V617F will depend on 
the expression pattern of multiple cytokine receptors, including those normally activated in 
these cells, e.g. the EpoR in erythroid cells, and those not, e.g. IFNGR1 and CXCR4. 
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Proliferation and differentiation of erythroid Epo- dependent progenitors depends on the 
regulated, sequential activation and then inactivation of the EpoR-JAK2 signaling pathway 
and presumably the absence of activation of Stat1 or Stat3(36). Since JAK2 V617F activates 
several non-erythroid signaling pathways including Stat1 in the early stages of erythroid 
differentiation, it is likely that activation of these non-erythroid signaling proteins interferes 
with normal erythroid signaling and blocks erythroid differentiation.
Indeed, we show that JAK2 V617F expressing cells express over 400 genes not normally 
expressed during terminal erythroid differentiation. Many of these genes are expressed 
predominantly in other hematopoietic lineages, including T cells, B cells, macrophages and 
megakaryocytes. Of these 400 genes 203 are abundantly expressed in macrophages and are 
activated by Stat1 and 171 are activated by Stat3; it is likely that in JAK2 V617F expressing 
cells these genes are also activated by Stat1 or Stat3. These non-erythroid pathways could be 
all or part of the explanation why erythroid progenitors expressing JAK2 V617F undergo 
excess numbers of early cell divisions. During differentiation of JAK2 V617F cells, the 
expression of most of these ~400 genes decreased gradually and were no longer enriched in 
erythroblasts expressing JAK2 V617F at 48 hours of differentiation. The drop in expression 
of these non-erythroid genes in JAK2 V617F expressing cells and the induction of normal 
erythroid important genes is consistent with the eventual normal terminal differentiation of 
these cells.
Importantly, activated Stat1 signaling has been found in mature erythroid cells from JAK2 
V617F ET patients (24), suggesting strong Stat1 signaling in terminal erythropoiesis. We 
also showed that JAK2 V617F expressing cells exhibit hyperactivation of Stat5. Consistent 
with this finding, depletion of Stat5 in JAK2 V617F knock-in mice disrupts hyperactive 
Epo-EpoR signaling and reverses production of excess red blood cells. Thus hyperactivation 
of Stat5 could be another reason why JAK2 V617 expressing erythroid progenitors undergo 
an excessive number of cell divisions.
Our study focuses on JAK2 V617F function at the terminal erythropoiesis stage. However, 
activation of abnormal signaling pathways in the HSCs and early progenitors also disturbs 
early hematopoietic development. Over-expression of hyperactive EpoR R129C in early 
hematopoietic progenitors, inducing strong Epo signaling, indeed leads to severe leukemia 
(43). JAK2 V617F alters the expression of several genes, including NF-E2, in early 
hematopoietic progenitors. Transgenic mouse models with elevated or mutated NF-E2 levels 
develop MPN-like phenotypes and leads to leukemic transformation (44,45). Moreover, 
JAK2 V617F has been shown to affect the self-renewal and differentiation of HSCs (12,16–
18). Therefore, JAK2 V617F ET patients or JAK2 V617F positive chronic granulocytic 
patients may have other defects in early hematopoiesis that results in erythroid progenitor 
cell defects.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ectopic expression of JAK2 V617F promotes proliferation of murine erythroid Epo- 
dependent progenitors, delays cell cycle exit and increases the number of CFU-Es
(a) Western blot shows the protein expression levels of JAK2 or JAK2 V617F in erythroid 
progenitors at 0, 24 and 48 hours after retroviral infection. GAPDH was used as a loading 
control. Numbers above the panels denote the ration of JAK2 to GAPDH. (b) Progenitors 
expressing Vector (circle) and JAK2 (square) expanded sixteen fold after 48 hours and then 
stopped dividing, while progenitors expressing JAK2 V617F (triangle) expanded four times 
more, resulting at 96 hours in a sixty-four fold increase in cell numbers. (c) As measured by 
PKH26 labeling, cultured Vector- and JAK2- expressing erythroid progenitors divided four 
times, whereas JAK2 V617F expressing erythroid progenitors underwent two additional 
divisions (**: p<0.01). (d) Plots of PKH26 fluorescence used to calculate the data in Panel c. 
(e) Cell cycle analyses were performed on erythroid progenitors expressing Vector, JAK2 
and JAK2 V617F during terminal differentiation. (f) The cell cycle analysis for erythroid 
cells expressing Vector, JAK2, and JAK2 V617F at 48 hours are replotted to more directly 
demonstrate the differences. (g) CFU-E colony assays utilizing a Methylcellulose-Based 
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Medium containing only Epo. Of 200 plated (0 hour control) lineage negative cells 
expressing Vector, JAK2 or JAK2 V617F, one half (100 cells) formed CFU-E colonies and 
thus were CFU-Es. Although cultures expressing only Vector or JAK2 exhibited no CFU-Es 
after 24 hours, erythroid progenitors expressing JAK2-V617F exhibited a four-fold increase 
in numbers of colony-forming CFU-Es after 24 hours. (h) Micrographs of typical erythroid 
colonies generated by zero-hour erythroid progenitors expressing only Vector or JAK2 or 
JAK2 V617F, as well as JAK2-V617F expressing progenitors after 24 hours of culture. Scale 
bar is 10 μm
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Figure 2. Erythroid progenitors expressing JAK2 V617F require a longer time to differentiate 
into normal reticulocytes as characterized by several criteria
At 48 hours of differentiation, erythroid progenitors expressing JAK2 V617F were 
undifferentiated compared to normal. (a) The size of JAK2 V617F- expressing cells at 48 hr. 
was larger than those of control vector or JAK2 cells, while the size of JAK2 V617F 
expressing cells at 96 hours was similar to that of control cells at 48 hr, as measured by 
forward scatter flow cytometry. (b) After 48 hr of culture JAK2 V617F- expressing cells also 
had lower erythroid-specific gene expression levels than JAK2 cells, as analyzed by 
quantitative PCR.
At 96 hour of differentiation, JAK2 V617F erythroid progenitors had differentiated to 
mature reticulocytes by several criteria. (c) JAK2 V617F erythroblasts had undergone 
enucleation, although the extent of enucleation was slightly lower than Vector and JAK2-
expressing erythroblasts at 48 h. (d) Hemoglobin content per cell of total JAK2 V617F- 
expressing erythroblasts was similar to that of Vector or JAK2 – expressing erythroblasts at 
48 hr, which was ~ 31 pg/cell. The cell pellet of 1.5 million JAK2 V617F erythroblasts at 96 
hours was red, as shown. (e) The size of JAK2 V617F reticulocytes formed at 96 hr was 
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similar to that of Vector and JAK2- expressing cells at 48 hr. (f) Flow cytometry 
measurement of enucleation of erythroblasts expressing Vector, JAK2 or JAK2 V617F at 48 
h, and JAK2 V617F at 96 h are shown. (*: p<0.05; **: p<0.01).
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Figure 3. Expression of mutant Epo receptor R129C did not delay erythroid differentiation
In the presence of Epo, erythroid progenitors expressing EpoR R129C underwent 
proliferation (a) and enucleation at 48 hr (c) at almost the same rate as those expressing 
Vector or wild-type (WT) EpoR. Importantly, the size of progenitors and enucleated 
reticulocytes expressing EpoR R129C at 48 hr of culture are similar to those of cells 
expressing Vector or WT EpoR (b), as measured by flow cytometry forward scatter. In the 
absence of Epo, only erythroid progenitors expressing EpoR R129C underwent proliferation 
(d) and enucleation (e) after 48 hr culture. (**: p<0.01).
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Figure 4. Microarray analysis of erythroid progenitors expressing Vector, JAK2 and JAK2 
V617F undergoing terminal differentiation
(a) Hierarchical clustering of global gene expression profiles for JAK2- expressing, JAK2 
V617F- expressing, and control cells during terminal erythropoiesis. (b) Expression of top 
600 genes upregulated in normal Ter119+ erythroblasts, relative to expression at 0 hour, in 
cells expressing either wild type JAK2 or JAK2 V617F. Induction of these genes is delayed 
in cells expressing JAK2 V617F. Color intensity indicates Log2 fold changes. (c) 
Enrichment plot of gene set “DNA replication” between JAK2 and JAK2 V617F cells at 48 
hours. (d) Log2 expression value of 36,551 mRNAs in JAK2 cells at 48 hours and JAK2 
V617F cells at 96 hours are plotted on a scatter plot with linear regression shown in black. 
(e) Leading edge analysis on top 20 gene sets significantly enriched in JAK2 V617F cells 
compared with JAK2 cells at 0 hour, showing the most common genes in the top gene sets.
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Figure 5. Activation of non-erythroid signaling pathways in erythroid progenitors expressing 
JAK2 V617F
(a) mRNAs encoding several cytokine receptors additional to EpoR, other JAKs additional 
to JAK2 and other STATs additional to STAT5 are highly expressed in purified murine fetal 
liver CFU-Es, characterized by Ter119 low and CD71 high. Data from Wong et. al.(25) (b) 
Western blots show expression of STAT1, STAT3, STAT5 and STAT6 in control, JAK2-
expressing, and JAK2 V617F-expressing erythroid progenitors at 2.5 hours after Epo 
simulation. Strikingly, hyper expression and activation (phosphorylation) of STAT1, STAT3 
and STAT5 were only found in progenitors expressing JAK2 V617F. Moreover, Western 
blots show expression of several cytokine receptors, including Glycoprotein 130 (GP130), 
cytokine receptor common beta chain (Csf2rb), Interferon gamma receptor 1(IFNGR1) and 
chemokine (C-X-C motif) receptor 4 (CXCR4) in erythroid progenitors at 2.5 hours culture 
after Epo simulation. Importantly, phosphorylation of IFNGR1 and CXCR4 were only found 
in progenitors expressing JAK2 V617F. GAPDH was used as loading control.
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Figure 6. In the absence of Epo erythroid progenitors expressing JAK2 V617F proliferate slower 
and do not differentiate
Without Epo, the proliferation rate of erythroid progenitors expressing JAK2 V617F is 
significantly lower than that in the presence of Epo (a). At 48, 72 and 96 hours, JAK2 
V617F cells cultured without Epo were stained with Hoechst and Ter119 antibody followed 
by flow cytometry showing the non-erythroid cells did not undergo enucleation, in contrast 
to JAK2 V617F- expressing cells cultured in the presence of Epo. The non-erythroid 
nucleated Ter119 negative cells were gated by black boxes (b). At 96 hours of differentiation 
without Epo, the percentage of Ter119 negative nucleated cells was significantly higher than 
in cultures with Epo. (**: p<0.01).
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Figure 7. Inhibition of Stat1 disrupted the erythroid hyper-proliferation of cells expressing JAK2 
V617F
(a) A Stat1 inhibitor, Fludorabine, blocked the proliferation of cells expressing JAK2 V617F, 
leading to a significant decrease in cell numbers during differentiation, while the Stat3 
inhibitor, Stattic, only moderately disturbed the proliferation of JAK2 V617F cells, 
comparing to control cells treated with DMSO. (b) Compared with cells treated with DMSO 
and Stattic, more cells treated with Fludorabine were Annexin V positive, suggesting more 
cells underwent apoptosis. (c) Western blots showed the Stat1 phosphorylation decreased in 
cells treated with Fludorabine, while Stat3 phosphorylation was also slightly reduced in cells 
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treated with Stattic, comparing to cells treated with DMSO. Western blot quantifications 
were done by Image J. The degree of Stat1 and Stat3 phosphorylation were represented by 
the rations of pStat1 to Stat1 and pStat3 to Stat3, respectively, which were normalized to 
those in cells treated with DMSO (set to 1.0). (*: p<0.05; **: p<0.01).
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